Purdue Pharma is a pharmaceutical company based in Stamford, Connecticut
It was founded in 1892 and has become known for its production of prescription opioids
The company gained significant attention and controversy for its role in promoting and marketing the highly addictive painkiller OxyContin
Purdue Pharma introduced OxyContin in 1996 and aggressively marketed it as a safe and effective solution for chronic pain
The drug gained popularity among doctors and patients, leading to widespread use
However, it also became highly sought after by individuals seeking to misuse or abuse opioids
The company faced allegations of downplaying the addictive nature of OxyContin and misleading both doctors and patients about its risks
In 2007, Purdue Pharma and three of its executives pleaded guilty to charges of misbranding OxyContin and paid a substantial fine
As the opioid crisis intensified in the United States, Purdue Pharma faced numerous lawsuits from states, cities, tribes, and individuals, accusing the company of contributing to the epidemic through its aggressive marketing practices
In 2019, the company filed for bankruptcy as part of a proposed settlement to resolve thousands of these lawsuits
Criticism of Purdue Pharma revolves around its alleged role in fueling the opioid crisis, as well as its aggressive marketing tactics and minimizing of addiction risks
The company has faced scrutiny for its profit-driven approach and the impact it has had on public health
The Wikipedia page on Purdue Pharma provides a comprehensive overview of the company's history, its involvement in the opioid crisis, legal actions taken against it, and the settlement attempts
It also covers the criticisms and controversies surrounding Purdue Pharma, including the impact on individuals and communities affected by the opioid epidemic
The page includes information on the company's bankruptcy filing and ongoing legal proceedings.
Purdue Pharma introduced OxyContin in 1996 and aggressively marketed it as a safe and effective solution for chronic pain. The drug gained popularity among doctors and patients, leading to widespread use. However, it also became highly sought after by individuals seeking to misuse or abuse opioids. The company faced allegations of downplaying the addictive nature of OxyContin and misleading both doctors and patients about its risks. In 2007, Purdue Pharma and three of its executives pleaded guilty to charges of misbranding OxyContin and paid a substantial fine. As the opioid crisis intensified in the United States, Purdue Pharma faced numerous lawsuits from states, cities, tribes, and individuals, accusing the company of contributing to the epidemic through its aggressive marketing practices. In 2019, the company filed for bankruptcy as part of a proposed settlement to resolve thousands of these lawsuits. Criticism of Purdue Pharma revolves around its alleged role in fueling the opioid crisis, as well as its aggressive marketing tactics and minimizing of addiction risks. The company has faced scrutiny for its profit-driven approach and the impact it has had on public health. The Wikipedia page on Purdue Pharma provides a comprehensive overview of the company's history, its involvement in the opioid crisis, legal actions taken against it, and the settlement attempts. It also covers the criticisms and controversies surrounding Purdue Pharma, including the impact on individuals and communities affected by the opioid epidemic. The page includes information on the company's bankruptcy filing and ongoing legal proceedings.